Abu Dhabi-based leading Artificial Intelligence and Cloud Computing company, G42 Healthcare has allied with US-based wearable technology firm WHOOP to provide its tracker to COVID-19 vaccine volunteers in UAE.
In a first of its kind initiative, the 24/7 fitness and health monitor will measure and track key biometrics of volunteers who participate in the world’s first Phase 3 trials of a COVID-19 vaccine being conducted in the region.
The Whoop4Humanity initiative ensures that volunteers who now join the clinical trials at ADNEC in Abu Dhabi and the Al Qarain Center in Sharjah, including those coming in for the second dose will be provided with a new wearable device which will enable them to check their daily heart rate, respiratory rate, heart rate variability, sleep performance, and more.
G42 Healthcare believes that WHOOP can be a powerful tool to boost the comprehensive volunteer healthcare management program by helping thousands of vaccine volunteers to self-monitor their well-being while measuring their fitness, sleep, and recovery levels during the trials. WHOOP provides valuable insights and actionable feedback around specific markers, thus encouraging better decision making for volunteers’ health.
WHOOP uniquely blends hardware, software, and industry-leading accurate measurements to help people sharpen the edges of performance, create impactful behavior change and a new set of positive individual habits, and empower them to optimize all facets of life.
Will Ahmed Founder and CEO WHOOP
“WHOOP is proud to partner with G42 Healthcare and participates in their innovative Phase III COVID-19 vaccine trial. The continuous biometric monitoring offered by WHOOP will help volunteers evaluate any changes to their health and help track their daily fitness levels. This partnership represents the future of healthcare: using continuous monitoring and artificial intelligence to better understand the effect of drugs, vaccines, and other treatments.”
The World Health Organization (WHO) and the United States Food & Drug Administration (USFDA) compliant Phase 3 trials of inactivated COVID-19 vaccine by Chinese pharmaceutical group Sinopharm CNBG began in Abu Dhabi on July 16 and is managed by G4 Healthcare in partnership with the Department of Health – Abu Dhabi, the UAE Ministry of Health and Prevention (MOHAP) and Abu Dhabi Health Services Company (SEHA).
